RS62038B1 - Ciljana tgf beta inhibicija - Google Patents

Ciljana tgf beta inhibicija

Info

Publication number: RS62038B1
Authority: RS; Serbia
Prior art keywords: tgf beta; beta inhibition; targeted tgf; targeted; inhibition
Prior art date: 2014-02-10

Application number

RS20210783A

Other languages

English (en)

Inventor

Kin-Ming Lo

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-10

Filing date

2015-02-10

Publication date

2021-07-30

2015-02-10 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2021-07-30 Publication of RS62038B1 publication Critical patent/RS62038B1/sr

Links

230000005764 inhibitory process Effects 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Neurology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)

RS20210783A 2014-02-10 2015-02-10 Ciljana tgf beta inhibicija RS62038B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461938048P	2014-02-10	2014-02-10
PCT/EP2015/052781 WO2015118175A2 (en)	2014-02-10	2015-02-10	TARGETED TGFβ INHIBITION
EP15717097.8A EP3105246B1 (en)	2014-02-10	2015-02-10	Targeted tgf beta inhibition

Publications (1)

Publication Number	Publication Date
RS62038B1 true RS62038B1 (sr)	2021-07-30

Family

ID=52988007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20210783A RS62038B1 (sr)	2014-02-10	2015-02-10	Ciljana tgf beta inhibicija

Country Status (28)

Country	Link
US (4)	US9676863B2 (sr)
EP (2)	EP3105246B1 (sr)
JP (2)	JP6731346B2 (sr)
KR (1)	KR102363008B1 (sr)
CN (2)	CN113549159A (sr)
AU (3)	AU2015213988B2 (sr)
BR (1)	BR112016014952A2 (sr)
CA (1)	CA2934979A1 (sr)
CL (1)	CL2016002017A1 (sr)
CY (1)	CY1124408T1 (sr)
DK (2)	DK3105246T3 (sr)
ES (2)	ES2876430T3 (sr)
HR (1)	HRP20210977T1 (sr)
HU (1)	HUE054873T2 (sr)
IL (2)	IL246968B (sr)
LT (1)	LT3105246T (sr)
MX (2)	MX381141B (sr)
NZ (1)	NZ721364A (sr)
PE (2)	PE20161096A1 (sr)
PH (1)	PH12016501549A1 (sr)
PL (1)	PL3105246T3 (sr)
PT (1)	PT3105246T (sr)
RS (1)	RS62038B1 (sr)
RU (2)	RU2021114500A (sr)
SG (2)	SG11201606577YA (sr)
SI (1)	SI3105246T1 (sr)
SM (1)	SMT202100542T1 (sr)
WO (1)	WO2015118175A2 (sr)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015027082A1 (en)	2013-08-22	2015-02-26	Acceleron Pharma, Inc.	Tgf-beta receptor type ii variants and uses thereof
EP3757130A1 (en)	2013-09-26	2020-12-30	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3105246T (lt)	2014-02-10	2021-08-25	Merck Patent Gmbh	Tikslinis tgf beta slopinimas
CN113583129A (zh)	2014-03-14	2021-11-02	诺华股份有限公司	针对lag-3的抗体分子及其用途
ES2771926T3 (es)	2014-09-13	2020-07-07	Novartis Ag	Terapias de combinación
TN2017000129A1 (en)	2014-10-14	2018-10-19	Dana Farber Cancer Inst Inc	Antibody molecules to pd-l1 and uses thereof
WO2016149201A2 (en)	2015-03-13	2016-09-22	Cytomx Therapeutics, Inc.	Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
EP3277716B1 (en)	2015-04-03	2020-06-24	XOMA Technology Ltd.	Treatment of cancer using inhibitors of tgf-beta and pd-1
ES2803655T3 (es)	2015-05-29	2021-01-28	Agenus Inc	Aticuerpos anti-ctla-4 y métodos de uso de los mismos
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
WO2017020291A1 (en)	2015-08-06	2017-02-09	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
US11219694B2 (en)	2015-09-24	2022-01-11	The University Of North Carolina At Chapel Hill	Methods and compositions for reducing metastases
US11583593B2 (en)	2016-01-14	2023-02-21	Synthis Therapeutics, Inc.	Antibody-ALK5 inhibitor conjugates and their uses
EP3432927A4 (en)	2016-03-24	2019-11-20	Gensun Biopharma Inc.	TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
CA3024465A1 (en) *	2016-05-17	2017-11-23	Genentech, Inc.	Stromal gene signatures for diagnosis and use in immunotherapy
JP7267012B2 (ja)	2016-05-27	2023-05-01	アジェナスインコーポレイテッド	抗ｔｉｍ－３抗体及びその使用方法
CA3031168A1 (en) *	2016-08-12	2018-02-15	Merck Patent Gmbh	Combination therapy for cancer
KR102617453B1 (ko)	2016-09-19	2023-12-26	현대모비스 주식회사	보조 표지판 인식 장치 및 그 방법
KR20240014617A (ko)	2016-09-27	2024-02-01	에피센트알엑스, 인코포레이티드	면역조정 융합 단백질
CN117586403A (zh)	2016-10-11	2024-02-23	艾吉纳斯公司	抗lag-3抗体及其使用方法
FI3551660T3 (fi)	2016-12-07	2023-12-11	Agenus Inc	Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
BR112019011582A2 (pt)	2016-12-07	2019-10-22	Agenus Inc.	anticorpos e métodos de utilização dos mesmos
US10537637B2 (en)	2017-01-05	2020-01-21	Gensun Biopharma Inc.	Checkpoint regulator antagonists
MX2019008001A (es) *	2017-01-07	2019-09-09	Merck Patent Gmbh	Regimenes de dosificacion y formas de dosificacion para inhibicion dirigida de factor beta de crecimiento transformante.
EP3568474A1 (en) *	2017-01-10	2019-11-20	Intrexon Corporation	Modulating expression of polypeptides via new gene switch expression systems
GB201700567D0 (en) *	2017-01-12	2017-03-01	Genagon Therapeutics Ab	Therapeutic agents
BR112019014510A2 (pt)	2017-01-13	2020-02-18	Agenus Inc.	Receptores de célula t que se ligam ao ny-eso-1 e métodos de uso dos mesmos
IL305536A (en)	2017-03-02	2023-10-01	Nat Res Council Canada	Tgf-b-receptor ectodomain fusion molecules and uses thereof
AU2018241774B2 (en) *	2017-03-30	2024-06-27	Merck Patent Gmbh	Combination of an anti-PD-L1 antibody and a DNA-PK inhibitor for the treatment of cancer
US11242385B2 (en)	2017-04-13	2022-02-08	Agenus Inc.	Anti-CD137 antibodies and methods of use thereof
WO2018195283A1 (en)	2017-04-19	2018-10-25	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
FI3618863T3 (fi)	2017-05-01	2023-09-01	Agenus Inc	Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
EP4241848A3 (en) *	2017-05-04	2023-11-01	Acceleron Pharma Inc.	Tgf-beta receptor type ii fusion proteins and uses thereof
CA3063087A1 (en) *	2017-05-09	2018-11-15	Julius Y. STRAUSS	Combination pdl1 and tgf-beta blockade in patients with hpv+ malignancies
TWI873080B (zh) *	2017-05-12	2025-02-21	大陸商江蘇恆瑞醫藥股份有限公司	含有ＴＧＦ-β受體的融合蛋白及其醫藥用途
WO2018222901A1 (en)	2017-05-31	2018-12-06	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
KR20200016899A (ko)	2017-06-01	2020-02-17	싸이톰스 테라퓨틱스, 인크.	활성화가능 항-pdl1 항체, 및 이의 이용 방법
CA3073055A1 (en)	2017-09-04	2019-03-07	Agenus Inc.	T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
EP3688037A4 (en)	2017-09-27	2021-09-15	EpicentRx, Inc.	IMMUNOMODULATOR FUSION PROTEINS
ES2984919T3 (es) *	2017-11-06	2024-10-31	Hoffmann La Roche	Procedimientos diagnósticos y terapéuticos para el cáncer
JP7348899B2 (ja) *	2017-12-08	2023-09-21	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性分子及びその使用
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CN119431579A (zh)	2018-03-09	2025-02-14	艾吉纳斯公司	抗cd73抗体及其使用方法
EP3765019A1 (en)	2018-03-14	2021-01-20	Merck Patent GmbH	Compounds and uses thereof to treat tumors in a subject
WO2019178364A2 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
EP3784688A2 (en)	2018-04-26	2021-03-03	Agenus Inc.	Heat shock protein-binding peptide compositions and methods of use thereof
CA3099527A1 (en)	2018-05-03	2019-11-07	Acceleron Pharma Inc.	Multispecific binders of tgf.beta.-superfamily ligands and uses thereof
US12168683B2 (en)	2018-05-03	2024-12-17	Acceleron Pharma Inc.	Binders of TGFβ-superfamily ligands and uses thereof
AU2019264229A1 (en)	2018-05-04	2020-12-03	Merck Patent Gmbh	Combined inhibition of PD-1/PD-L1, TGFβ and DNA-PK for the treatment of cancer
WO2019222252A1 (en) *	2018-05-15	2019-11-21	Merck Patent Gmbh	Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
EP3793613B1 (en)	2018-05-17	2025-01-01	Bolt Biotherapeutics, Inc.	Immunoconjugates
SG11202012426WA (en) *	2018-06-13	2021-01-28	Merck Patent Gmbh	Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
JP7468903B2 (ja)	2018-06-17	2024-04-16	エルアンドエルバイオファーマカンパニーリミテッド	Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用
TW202019959A (zh) *	2018-06-22	2020-06-01	德商馬克專利公司	用於治療膽道癌的標靶性tgf-b抑制之給藥方案
JP2021532170A (ja)	2018-06-29	2021-11-25	ジェンサンバイオファーマ、インコーポレイテッドGensun Biopharma, Inc.	三重特異性アンタゴニスト
CA3105360A1 (en) *	2018-07-02	2020-01-09	Merck Patent Gmbh	Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
CA3105448A1 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
KR20210042909A (ko) *	2018-07-09	2021-04-20	프레시전 인코포레이티드	융합 구조물 및 그의 이용 방법
CN113271962A (zh) *	2018-08-22	2021-08-17	默克专利有限公司	利用靶向TGF-β抑制的三阴性乳腺癌的治疗
CN113164777B (zh)	2018-09-27	2024-12-13	马伦戈治疗公司	Csf1r/ccr2多特异性抗体
EP3873611A1 (en)	2018-11-01	2021-09-08	Merck Patent GmbH	Anti-tim-3 antibodies
JP2022505923A (ja) *	2018-11-01	2022-01-14	メルクパテントゲーエムベーハー	抗ｔｉｍ－３抗体を投与する方法
US20220017601A1 (en)	2018-11-09	2022-01-20	Jiangsu Hengrui Medicine Co., Ltd.	TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG11202105975SA (en) *	2018-12-06	2021-07-29	Guangdong Tcrcure Biopharma Technology Co Ltd	Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
EP3927745A1 (en)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
CN114026122B (zh)	2019-02-21	2024-12-31	马伦戈治疗公司	结合t细胞相关癌细胞的多功能分子及其用途
WO2020190734A1 (en)	2019-03-15	2020-09-24	Bolt Biotherapeutics, Inc.	Immunoconjugates targeting pd-l1
CN114206926B (zh) *	2019-06-10	2022-06-17	山东博安生物技术股份有限公司	抗PDL1和TGFβ的双功能融合蛋白及其用途
AU2020291014B2 (en)	2019-06-13	2025-06-05	Bolt Biotherapeutics, Inc.	Aminobenzazepine compounds, immunoconjugates, and uses thereof
CN110218260A (zh) *	2019-06-24	2019-09-10	王跃驹	植物作为宿主在表达m7842中的应用
US10851157B2 (en)	2019-07-01	2020-12-01	Gensun Biopharma, Inc.	Antagonists targeting the TGF-β pathway
US20210107969A1 (en) *	2019-07-09	2021-04-15	The Johns Hopkins University	Molecules, compositions and methods for treatment of cancer
CN112239507A (zh) *	2019-07-17	2021-01-19	鸿运华宁（杭州）生物医药有限公司	ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
EP4013507A1 (en) *	2019-08-15	2022-06-22	NantBio, Inc.	Tgf-beta trap
WO2021037184A1 (zh)	2019-08-30	2021-03-04	正大天晴药业集团南京顺欣制药有限公司	一种靶向PD-L1和TGF-β的融合蛋白及其用途
CA3152027A1 (en)	2019-08-30	2021-03-04	Agenus Inc.	Anti-cd96 antibodies and methods of use thereof
EP4025254A1 (en)	2019-09-03	2022-07-13	Bolt Biotherapeutics, Inc.	Aminoquinoline compounds, immunoconjugates, and uses thereof
EP4025255A1 (en)	2019-09-04	2022-07-13	Bolt Biotherapeutics, Inc.	Immunoconjugate synthesis method
CN112442132A (zh) *	2019-09-05	2021-03-05	复旦大学	靶向肿瘤的重组双功能融合蛋白及其应用
MX2022003740A (es)	2019-09-30	2022-05-02	Bolt Biotherapeutics Inc	Inmunoconjugados de aminobenzazepina unidos a amida y usos de estos.
TWI832013B (zh) *	2019-09-30	2024-02-11	大陸商諾納生物（蘇州）有限公司	一種抗pd-l1抗原結合蛋白及其應用
CN114616251B (zh) *	2019-10-21	2024-05-24	南京维立志博生物科技有限公司	靶向PD-1和TGFβ的重组蛋白
CA3155077A1 (en)	2019-10-25	2021-04-29	Romas Kudirka	Thienoazepine immunoconjugates, and uses thereof
US20230044248A1 (en) *	2019-11-01	2023-02-09	Ares Trading S.A.	COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
AU2020379201A1 (en)	2019-11-05	2022-05-26	Glaxosmithkline Intellectual Property (No. 4) Ltd.	Combined inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer
TW202128763A (zh) *	2019-11-12	2021-08-01	大陸商江蘇恆瑞醫藥股份有限公司	含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
US20230242675A1 (en) *	2019-11-27	2023-08-03	Shanghai Epimab Biotherapeutics Co., Ltd.	TGF[beta]/PD-L1 BISPECIFIC BINDING PROTEINS
WO2021115456A1 (en) *	2019-12-11	2021-06-17	Wuxi Biologics (Shanghai) Co., Ltd.	BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFβ
EP3838260A1 (en)	2019-12-20	2021-06-23	Ares Trading S.A.	Igg:tgf rii fusion protein composition
BR112022011775A2 (pt) *	2019-12-20	2022-08-30	Ares Trading Sa	Composição de proteína de fusão igg:tgfssrii
CN113004414B (zh) *	2019-12-20	2022-09-06	广东菲鹏制药股份有限公司	抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
CN113121699A (zh) *	2019-12-30	2021-07-16	国典(北京)医药科技有限公司	Pttrap1双特异性融合蛋白及其应用
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
KR20220107251A (ko) *	2020-01-09	2022-08-02	에프. 호프만-라 로슈 아게	새로운 4-1bbl 삼량체-함유 항원 결합 분자
CN115175939A (zh)	2020-01-21	2022-10-11	博尔特生物治疗药物有限公司	抗pd-l1抗体
CA3165337A1 (en) *	2020-01-21	2021-07-29	Michael N. ALONSO	Anti-pd-l1 antibodies
EP4107190A4 (en) *	2020-02-18	2024-03-20	Nanjing GenScript Biotech Co., Ltd.	FUSION PROTEINS AND USES THEREOF
EP4093779A4 (en) *	2020-02-25	2024-03-06	Wuxi Biologics Ireland Limited	BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
US20220204626A1 (en) *	2020-03-20	2022-06-30	Remegen Co., Ltd.	Bispecific fusion protein and application thereof
WO2021209358A1 (en)	2020-04-14	2021-10-21	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
WO2021209458A1 (en)	2020-04-14	2021-10-21	Ares Trading S.A.	Combination treatment of cancer
CA3180321A1 (en)	2020-04-24	2021-10-28	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2023523480A (ja)	2020-04-28	2023-06-06	ザロックフェラーユニバーシティー	中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法
KR20230005907A (ko)	2020-05-01	2023-01-10	볼트 바이오테라퓨틱스 인코퍼레이티드	항-dectin-2 항체
US20230293716A1 (en)	2020-05-08	2023-09-21	Bolt Biotherapeutics, Inc.	Elastase-substrate, peptide linker immunoconjugates, and uses thereof
EP4172208A2 (en) *	2020-06-26	2023-05-03	Sorrento Therapeutics, Inc.	Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
EP4178680A4 (en)	2020-07-10	2024-07-31	Precigen, Inc.	FUSION CONSTRUCTS AND THEIR METHODS OF USE
US20230365653A1 (en) *	2020-07-24	2023-11-16	Mabwell (shanghai) Bioscience Co., Ltd.	Tgf-beta rii mutant and fusion protein thereof
US11028174B1 (en)	2020-07-28	2021-06-08	Lepu Biopharma Co., Ltd.	Bifunctional molecules targeting PD-L1 and TGF-β
AU2021317376A1 (en) *	2020-07-28	2023-02-23	Lepu Biopharma Co., Ltd.	Bifunctional molecules targeting PD-l1 and TGF-beta
WO2022042537A1 (zh) *	2020-08-24	2022-03-03	江苏恒瑞医药股份有限公司	TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途
CA3190573A1 (en)	2020-08-26	2022-03-03	Andreas Loew	Methods of detecting trbc1 or trbc2
JP2023539645A (ja)	2020-08-26	2023-09-15	マレンゴ・セラピューティクス，インコーポレーテッド	Ｎｋｐ３０に結合する抗体分子およびその使用
AU2021331075A1 (en)	2020-08-26	2023-04-06	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
CN114106190B (zh)	2020-08-31	2025-04-08	普米斯生物技术(珠海)有限公司	一种抗vegf/pd-l1双特异性抗体及其用途
WO2022042715A1 (zh) *	2020-08-31	2022-03-03	杭州九源基因工程有限公司	靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
WO2022057061A1 (en) *	2020-09-16	2022-03-24	Suzhou Neologics Bioscience Co., Ltd.	Pd-l1 antibodies, fusion proteins, and uses thereof
EP4165086A4 (en) *	2020-09-16	2024-07-31	Suzhou Neologics Bioscience Co., Ltd.	Pd-l1 antibodies, fusion proteins, and uses thereof
WO2022063114A1 (zh) *	2020-09-23	2022-03-31	海正生物制药有限公司	Tgfbr2-ecd突变体及包含其的融合蛋白与应用
CN116323657B (zh) *	2020-09-24	2023-12-08	上海齐鲁制药研究中心有限公司	同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CN114349867B (zh) *	2020-10-14	2024-05-28	广东菲鹏制药股份有限公司	融合蛋白及其应用
JP2023550900A (ja)	2020-11-02	2023-12-06	アレストレーディングソシエテアノニム	がんの組み合わせ治療
CN116801906A (zh)	2020-11-02	2023-09-22	阿雷斯贸易股份有限公司	癌症的联合治疗
CN114573701A (zh) *	2020-12-02	2022-06-03	上海华奥泰生物药业股份有限公司	抗PD-L1/TGF-β双功能抗体及其用途
EP4259210A2 (en)	2020-12-11	2023-10-18	Bolt Biotherapeutics, Inc.	Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en)	2020-12-11	2022-06-23	Bolt Biotherapeutics, Inc.	Anti-cea immunoconjugates, and uses thereof
EP4259209A1 (en)	2020-12-11	2023-10-18	Bolt Biotherapeutics, Inc.	Anti-pd-l1 immunoconjugates, and uses thereof
CN116917334A (zh)	2021-02-22	2023-10-20	浙江道尔生物科技有限公司	一种具有抗癌活性的多结构域融合蛋白
IL305427A (en)	2021-03-02	2023-10-01	Glaxosmithkline Ip Dev Ltd	Substituted pyridines as dnmt1 inhibitors
TW202304520A (zh)	2021-03-26	2023-02-01	美商博特生物治療公司	２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
TW202300175A (zh)	2021-03-26	2023-01-01	美商博特生物治療公司	２－胺基－４－羧醯胺－苯并氮呯免疫結合物及其用途
CA3218697A1 (en)	2021-05-03	2022-11-10	Merck Patent Gmbh	Her2 targeting fc antigen binding fragment-drug conjugates
CN114773485B (zh) *	2021-05-11	2024-05-17	江苏先声药业有限公司	抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
IL308818A (en)	2021-05-25	2024-01-01	Merck Patent Gmbh	Egfr targeting fc antigen binding fragment-drug conjugates
EP4351640A1 (en)	2021-06-07	2024-04-17	Ares Trading S.A.	Combination treatment of cancer
JP2024534263A (ja) *	2021-08-27	2024-09-18	セラノティックスカンパニーリミテッド	Ｂ７－Ｈ３及びＴＧＦβに特異的に結合する二重特異性分子、並びにその用途
WO2023141724A1 (en)	2022-01-28	2023-08-03	35Pharma Inc.	Activin receptor type iib variants and uses thereof
CN114990129B (zh) *	2022-05-11	2023-02-03	北京贝来生物科技有限公司	表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
CN119213034A (zh)	2022-05-17	2024-12-27	苏州创胜医药集团有限公司	双功能蛋白质及其制剂和用途
WO2024137619A1 (en)	2022-12-20	2024-06-27	Bolt Biotherapeutics, Inc.	Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024173384A1 (en)	2023-02-14	2024-08-22	Bolt Biotherapeutics, Inc.	Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en)	2023-03-03	2024-09-12	Bolt Biotherapeutics, Inc.	Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024216028A1 (en)	2023-04-12	2024-10-17	Agenus Inc.	Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024216089A1 (en)	2023-04-13	2024-10-17	Bolt Biotherapeutics, Inc.	Anti-dectin-2 antibody combination therapy
WO2025096770A1 (en) *	2023-10-31	2025-05-08	Immunitybio, Inc.	Multi-chain chimeric polypeptides and uses thereof
KR20250078792A (ko) *	2023-11-24	2025-06-04	주식회사 메드팩토	피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5785682A (en)	1995-03-22	1998-07-28	Abbott Laboratories	Pre-filled syringe drug delivery system
JP2001515360A (ja) *	1997-04-18	2001-09-18	バイオジェン，インコーポレイテッド	▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
DK1252192T3 (da)	2000-02-11	2006-11-20	Merck Patent Gmbh	Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
CN1330664C (zh)	2001-03-07	2007-08-08	默克专利有限公司	用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
JP2005112812A (ja) *	2003-10-09	2005-04-28	Zeria Pharmaceut Co Ltd	リン酸化部位特異的抗体及びそれを用いたスクリーニング方法
RU2006122519A (ru)	2003-12-24	2008-01-27	Сайос, Инк. (Us)	Лечение злокачественных глиом ингибиторами тфр-бэта
US7670595B2 (en)	2004-06-28	2010-03-02	Merck Patent Gmbh	Fc-interferon-beta fusion proteins
US7795389B2 (en)	2004-09-28	2010-09-14	The Board Of Regents Of The University Of Texas System	Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
UA99701C2 (ru)	2005-07-01	2012-09-25	Медарекс, Инк.	Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1)
CN101541832B (zh) *	2006-09-07	2014-11-12	克鲁塞尔荷兰公司	能中和流感病毒h5n1的人结合分子及其应用
WO2008157367A1 (en)	2007-06-15	2008-12-24	Genzyme Corporation	Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US20140127200A1 (en)	2008-01-03	2014-05-08	The Scripps Research Institute	Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
WO2009152610A1 (en)	2008-06-20	2009-12-23	The Royal Institution For The Advancement Of Learning/Mcgill University	Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US20110177070A1 (en)	2008-07-02	2011-07-21	Emergent Product Development Seatlle, LLC	TGF-Beta Antagonist Multi-Target Binding Proteins
HUE034832T2 (hu) *	2008-12-09	2021-12-28	Hoffmann La Roche	Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
FR2944448B1 (fr) *	2008-12-23	2012-01-13	Adocia	Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
CA2748889A1 (en)	2009-03-18	2010-09-23	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
ES2639056T3 (es)	2009-10-28	2017-10-25	Abbvie Biotherapeutics Inc.	Anticuerpos anti-EGFR y sus usos
KR101790767B1 (ko)	2009-11-24	2017-10-26	메디뮨 리미티드	Ｂ７―ｈ１에 대한 표적화된 결합 물질
CA2785907A1 (en) *	2009-12-29	2011-07-28	Emergent Product Development Seattle, Llc	Ron binding constructs and methods of use thereof
US20130129723A1 (en) *	2009-12-29	2013-05-23	Emergent Product Development Seattle, Llc	Heterodimer Binding Proteins and Uses Thereof
MX2012009554A (es)	2010-02-23	2012-11-23	Hoffmann La Roche	Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
US8993524B2 (en) *	2010-03-05	2015-03-31	The Johns Hopkins University	Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
TW201840336A (zh) *	2011-08-01	2018-11-16	美商建南德克公司	利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
PT2785375T (pt) *	2011-11-28	2020-10-29	Merck Patent Gmbh	Anticorpos anti-pd-l1 e usos destes
CA3004695C (en) *	2012-04-30	2020-08-04	Biocon Limited	Targeted/immunomodulatory fusion proteins and methods for making same
MX363872B (es)	2012-05-31	2019-04-05	Genentech Inc	Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cáncer.
US10010608B2 (en)	2013-05-31	2018-07-03	Merck Sharp & Dohme Corp.	Combination therapies for cancer
BR112016013963A2 (pt)	2013-12-17	2017-10-10	Genentech Inc	terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
LT3105246T (lt)	2014-02-10	2021-08-25	Merck Patent Gmbh	Tikslinis tgf beta slopinimas
GB201403875D0 (en)	2014-03-05	2014-04-16	Cantargia Ab	Novel antibodies and uses thereof
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
AU2015303135B2 (en)	2014-08-15	2021-05-20	Merck Patent Gmbh	SIRP-alpha immunoglobulin fusion proteins

2015
- 2015-02-10 LT LTEP15717097.8T patent/LT3105246T/lt unknown
- 2015-02-10 PE PE2016001267A patent/PE20161096A1/es unknown
- 2015-02-10 US US14/618,454 patent/US9676863B2/en active Active
- 2015-02-10 RU RU2021114500A patent/RU2021114500A/ru unknown
- 2015-02-10 SG SG11201606577YA patent/SG11201606577YA/en unknown
- 2015-02-10 SI SI201531639T patent/SI3105246T1/sl unknown
- 2015-02-10 KR KR1020167024679A patent/KR102363008B1/ko active Active
- 2015-02-10 SG SG10202108879SA patent/SG10202108879SA/en unknown
- 2015-02-10 CN CN202110830081.8A patent/CN113549159A/zh active Pending
- 2015-02-10 DK DK15717097.8T patent/DK3105246T3/da active
- 2015-02-10 PL PL15717097T patent/PL3105246T3/pl unknown
- 2015-02-10 BR BR112016014952A patent/BR112016014952A2/pt not_active Application Discontinuation
- 2015-02-10 AU AU2015213988A patent/AU2015213988B2/en active Active
- 2015-02-10 HR HRP20210977TT patent/HRP20210977T1/hr unknown
- 2015-02-10 PT PT157170978T patent/PT3105246T/pt unknown
- 2015-02-10 EP EP15717097.8A patent/EP3105246B1/en active Active
- 2015-02-10 ES ES15717097T patent/ES2876430T3/es active Active
- 2015-02-10 SM SM20210542T patent/SMT202100542T1/it unknown
- 2015-02-10 JP JP2016546949A patent/JP6731346B2/ja active Active
- 2015-02-10 WO PCT/EP2015/052781 patent/WO2015118175A2/en active Application Filing
- 2015-02-10 EP EP21165709.3A patent/EP3889172B1/en active Active
- 2015-02-10 PE PE2020002093A patent/PE20210168A1/es unknown
- 2015-02-10 HU HUE15717097A patent/HUE054873T2/hu unknown
- 2015-02-10 RU RU2016135062A patent/RU2752424C2/ru active
- 2015-02-10 CA CA2934979A patent/CA2934979A1/en active Pending
- 2015-02-10 ES ES21165709T patent/ES2992668T3/es active Active
- 2015-02-10 NZ NZ721364A patent/NZ721364A/en unknown
- 2015-02-10 DK DK21165709.3T patent/DK3889172T3/da active
- 2015-02-10 MX MX2016010067A patent/MX381141B/es unknown
- 2015-02-10 CN CN201580007865.3A patent/CN106103488B/zh active Active
- 2015-02-10 RS RS20210783A patent/RS62038B1/sr unknown
2016
- 2016-07-27 IL IL246968A patent/IL246968B/en active IP Right Grant
- 2016-08-03 MX MX2021003685A patent/MX2021003685A/es unknown
- 2016-08-04 PH PH12016501549A patent/PH12016501549A1/en unknown
- 2016-08-10 CL CL2016002017A patent/CL2016002017A1/es unknown
2017
- 2017-06-08 US US15/617,876 patent/US20180002436A1/en not_active Abandoned
2019
- 2019-07-25 US US16/522,304 patent/US11370819B2/en active Active
- 2019-10-11 AU AU2019246876A patent/AU2019246876B2/en active Active
2020
- 2020-07-06 JP JP2020116566A patent/JP2020174674A/ja active Pending
2021
- 2021-03-16 IL IL281565A patent/IL281565B/en unknown
- 2021-06-23 CY CY20211100564T patent/CY1124408T1/el unknown
2022
- 2022-01-20 AU AU2022200365A patent/AU2022200365A1/en active Pending
- 2022-06-07 US US17/834,458 patent/US20230056881A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2876430T3 (es)	2021-11-12
SI3105246T1 (sl)	2021-11-30
PH12016501549A1 (en)	2016-10-03
IL246968A0 (en)	2016-09-29
EP3105246B1 (en)	2021-03-31
DK3105246T3 (da)	2021-06-14
SMT202100542T1 (it)	2021-11-12
CN106103488A (zh)	2016-11-09
AU2019246876B2 (en)	2021-10-21
BR112016014952A2 (pt)	2017-09-19
NZ721364A (en)	2023-04-28
AU2015213988A1 (en)	2016-07-07
WO2015118175A3 (en)	2015-10-08
MX2021003685A (es)	2021-06-04
RU2016135062A3 (sr)	2018-12-12
EP3889172A1 (en)	2021-10-06
IL281565A (en)	2021-05-31
JP2017506217A (ja)	2017-03-02
HRP20210977T1 (hr)	2021-09-17
CA2934979A1 (en)	2015-08-13
WO2015118175A2 (en)	2015-08-13
KR20160119197A (ko)	2016-10-12
US9676863B2 (en)	2017-06-13
AU2022200365A1 (en)	2022-02-17
IL246968B (en)	2021-04-29
US11370819B2 (en)	2022-06-28
AU2019246876A1 (en)	2019-10-31
EP3105246A2 (en)	2016-12-21
US20150225483A1 (en)	2015-08-13
US20230056881A1 (en)	2023-02-23
RU2752424C2 (ru)	2021-07-28
AU2015213988B2 (en)	2019-07-11
SG10202108879SA (en)	2021-09-29
MX2016010067A (es)	2016-10-07
PE20210168A1 (es)	2021-01-28
RU2016135062A (ru)	2018-03-15
KR102363008B1 (ko)	2022-02-16
JP6731346B2 (ja)	2020-07-29
CL2016002017A1 (es)	2017-06-09
US20180002436A1 (en)	2018-01-04
PE20161096A1 (es)	2016-10-22
PT3105246T (pt)	2021-06-28
SG11201606577YA (en)	2016-09-29
IL281565B (en)	2021-12-01
ES2992668T3 (en)	2024-12-16
DK3889172T3 (da)	2024-06-17
HUE054873T2 (hu)	2021-10-28
JP2020174674A (ja)	2020-10-29
CN113549159A (zh)	2021-10-26
LT3105246T (lt)	2021-08-25
CY1124408T1 (el)	2022-07-22
RU2021114500A (ru)	2021-06-07
CN106103488B (zh)	2021-07-30
US20200055949A1 (en)	2020-02-20
EP3889172B1 (en)	2024-05-01
MX381141B (es)	2025-03-12
PL3105246T3 (pl)	2021-11-29

Publication	Publication Date	Title
IL304663A (en)	2023-09-01	combination
IL281565A (en)	2021-05-31	Targeted inhibition of TGF-beta
AU362002S (en)	2015-05-28	Kiosk
IL247073A0 (en)	2016-09-29	combination
SG10201505703PA (en)	2016-03-30	Transfer unit
GB2524311B (en)	2016-03-09	Centraliser
GB201406977D0 (en)	2014-06-04	Fluoroalkylfluorene derivatives
PL3418273T3 (pl)	2022-08-01	Pochodne flawaglin
AP2016009545A0 (en)	2016-11-30	Naphthyridinedione derivatives
IL252269A0 (en)	2017-07-31	History of benzothiazole antibacterials
HUE046518T2 (hu)	2020-03-30	Cikloalkilcsoporthoz kapcsolt diheterociklusos származékok
IL250405A0 (en)	2017-03-30	Antibacterial sideromycins
SG10201507112YA (en)	2016-04-28	Furnace
GB2531577B (en)	2017-08-09	Transfer case
GB2526684B (en)	2017-05-31	Ceramic-backed elbow
SG11201508723QA (en)	2016-03-30	Underwear
GB2525001B (en)	2016-03-09	Centraliser
GB201414430D0 (en)	2014-10-01	Scafold adjuster
GB201407758D0 (en)	2014-06-18	Beta beats
PH32014000148S1 (en)	2014-02-26	Undershirt
GB201419400D0 (en)	2014-12-17	Concept 82c
GB201420991D0 (en)	2015-01-07	Confectionary
GB201419176D0 (en)	2014-12-10	Attachment arrangement
GB201407898D0 (en)	2014-06-18	Proximity
GB201400930D0 (en)	2014-03-05	Concept 82c